<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401581</url>
  </required_header>
  <id_info>
    <org_study_id>14-PP-07</org_study_id>
    <nct_id>NCT02401581</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours</brief_title>
  <acronym>PRECOCE</acronym>
  <official_title>Study ¨PRECOCE Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Benign hypertrophy of the prostate (BPH) is the most frequent pathology in the urinary tract&#xD;
      of middle-aged men. In recent years, to enable BPH treatment with larger volumes and to&#xD;
      reduce the risk of hemorrhage known to be associated to the transurethral resection of&#xD;
      prostate treatment, transurethral photovaporisation of the prostate (PVP ) with the&#xD;
      GreenLight (GL) XPS 180 W was developed. Therefore, the question arises to maximally reduce&#xD;
      the length of catheterization to facilitate outpatient surgical management of prostate&#xD;
      adenoma.&#xD;
&#xD;
      In the investigators study, the investigators propose to evaluate the failure rate of an&#xD;
      early removal of the catheter 3 hours post-operative after a PVP procedure with GL 180 W/XPS&#xD;
      in selected patients on general anesthesia or spinal anesthesia. To this end, the&#xD;
      investigators realize a national multicenter prospective study including 300 patients. The&#xD;
      effectiveness of this model of management is defined by absence of a need for&#xD;
      re-catheterization in the post -operative period of 24 hours.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2015</start_date>
  <completion_date type="Actual">June 8, 2021</completion_date>
  <primary_completion_date type="Actual">August 21, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>failure rate of a limited catheterization duration of 3 hours post- operative</measure>
    <time_frame>at three hours post surgery</time_frame>
    <description>• The failure rate of a limited catheterization duration of 3 hours post- operative is defined by a need of recatheterizatrion within 24 hours post- GL with PVP XPS 180W . The catheterization remains indicated in case of macroscopic hematuria RAU or if no natural urination is possible</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dose of energy</measure>
    <time_frame>during 24 hours hospitalisation</time_frame>
    <description>The total dose of energy delivered to the tissue induring the intervention will be expressed and collected by means of the instrumentation of the GL-XPS console.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of recatherization</measure>
    <time_frame>during 24 hours hospitalisation</time_frame>
    <description>The duration of recatherization is regarded as the total cumulative duration of catheterization regardless of the number of attempts for removale when it is a failure. The average duration of resondage counts only recatheterizations occurring in the first week which may be considered as due to PVP with GL XPS 180W followed by a shortened catheterization of 3 hours post- operatively . The duration of recatherization is defined from the time when it was done in thefirst week post- operative until urinary recovery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Benign Prostatic Hypertrophy</condition>
  <arm_group>
    <arm_group_label>rate of early removal of the catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In our study, we propose to evaluate the failure rate of an early removal of the catheter 3 hours post-operative after a PVP procedure with GL 180 W/XPS in selected patients on general anesthesia or spinal anesthesia for limiting autonomic effects on the bladder and ensure fastest possible recovery of voiding .</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Catheter</intervention_name>
    <description>The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).</description>
    <arm_group_label>rate of early removal of the catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients with lower urinary tract symptoms (LUTS )&#xD;
&#xD;
          2. IPSS≥ 15 despite medical treatment &gt; 1 month if monotherapy or &gt; 3 months if&#xD;
             bitherapie OR acute urinary retention ( RAU ) non-medical after the 1st failure to&#xD;
             remove the catheter OR acute prostatitis OR macroscopic haematuria of prostatic origin&#xD;
&#xD;
          3. prostate volume &gt; 30 cc by transrectal ultrasonography ;&#xD;
&#xD;
          4. IPSS Qol ≥ 3 has at inclusion ;&#xD;
&#xD;
          5. PSA ≤ 4 ng / ml ;&#xD;
&#xD;
          6. if PSA between 4 and 10 then PSA L/T ≥25 % or negative PBP &lt;6 months .&#xD;
&#xD;
          7. Accommodation &lt;50 km;&#xD;
&#xD;
          8. company available for the return at home and monitoring first post- operative night .&#xD;
&#xD;
          9. patient sign the informed consent&#xD;
&#xD;
         10. patient covered by social security or other health insurance&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. post- voiding residue &gt; 250 cc by suprapubic ultrasound not older than &lt; 45 days&#xD;
&#xD;
          2. prostate volume &gt; 100 cc by transrectal ultrasound not older than 45 days&#xD;
&#xD;
          3. urological antecedents : o urethral stenosis or cervical disease&#xD;
&#xD;
               -  UTI in progress&#xD;
&#xD;
               -  SAD patient or self-catheterization&#xD;
&#xD;
               -  obstructive hydronephrosis + / - renal failure&#xD;
&#xD;
               -  vesical calculi&#xD;
&#xD;
               -  cancer of the prostate treated or untreated&#xD;
&#xD;
               -  bladder tumor associated&#xD;
&#xD;
               -  Interstitial cystitis ( symptom or biopsy)&#xD;
&#xD;
          4. antecedent of the prostate surgery&#xD;
&#xD;
          5. neurologic bladder ( parkinsonian syndrome , multiple sclerosis , lupus, neuropathy,&#xD;
             Diabetic, cauda equina syndrome )&#xD;
&#xD;
          6. criteria related concomitant medications that can not be stopped at least &lt; 48 hours&#xD;
             before PVP with GL XPS 180 W&#xD;
&#xD;
          7. contra indication for outpatient care for medical reason&#xD;
&#xD;
          8. contra indication of a product analgesic according to protocol&#xD;
&#xD;
          9. patient inability to understand and sign the informed consent as well as completing&#xD;
             the questionnaires&#xD;
&#xD;
         10. ASA Score &gt; 3 .&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DURAND Matthieu, Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Urologie, CHU de Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Grasse - urologie</name>
      <address>
        <city>Grasse</city>
        <state>Alpes-maritimes</state>
        <zip>06130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Urologie</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH privé St Brieuc</name>
      <address>
        <city>Saint-Brieuc</city>
        <state>Cote D'armor</state>
        <zip>22003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Urologie Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Monsouris urologie</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM - Urologie - Hôpital Conception</name>
      <address>
        <city>Marseille</city>
        <state>Paca</state>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <state>Vendée</state>
        <zip>37 044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brest Urologie</name>
      <address>
        <city>Brest</city>
        <zip>2609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges -Urologie - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique les Bleuets</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

